What are the side effects of Tevimbra (Tislelizumab-jsgr)?

Tevimbra (Tislelizumab-jsgr) is an immune checkpoint inhibitor used to treat esophageal squamous cell carcinoma and has been widely used clinically in recent years. Despite its remarkable efficacy, patients may experience some side effects during treatment with Tevimbra, and these side effects vary among different patients.

In clinical studies,The most common side effects of Tevimbra include: increased blood sugar, decreased hemoglobin, lymphopenia, decreased sodium, decreased albumin, increased alkaline phosphatase, anemia, fatigue, increased aspartate aminotransferase (AST), musculoskeletal pain, weight loss, increased alanine aminotransferase (ALT), and cough. The incidence rates of these adverse reactions are all above 20%, indicating that these reactions require high attention from patients and doctors.

Elevated blood sugar isan important adverse reaction during Tevimbra treatment. This may be related to the activation of the immune system, and some patients need to monitor blood sugar levels during treatment and intervene if necessary. Secondly, the decrease in hemoglobin and lymphocytes may affect the patient's overall health, leading to anemia and decreased immune function, thereby increasing the risk of infection.

In addition, abnormal liver function is also one of the noteworthy side effects. Elevated levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) may indicate liver damage. Therefore, during treatment, patients need to undergo regular liver function tests to detect and deal with possible liver damage in a timely manner.

In addition to the common side effects mentioned above, Tevimbra has also experienced some adverse events related to skin and subcutaneous tissue diseases after its launch. Especially Stevens-Johnson syndrome and toxic epidermal necrolysis. Although the incidence of these serious adverse reactions is low, they still require great attention from the medical community due to their potential fatality. Once relevant symptoms, such as rash, mucosal damage, etc., appear, the drug must be stopped immediately and appropriate treatment must be carried out.

Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08ef1e3e-496f-4b0b-94ee-fbba3cc1985a##